Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 517-533 , December 2007

DPP-4 inhibitors

  • Bo Ahrén, MD, PhD (Professor)

      Affiliations

    • Corresponding Author InformationTel.: +46 46 2220758; Fax: +46 46 2220858.

References 

  1. Elrick H, Stimmler L, Hlad CJ, et al. Plasma insulin response to oral and intravenous glucose administration. The Journal of Clinical Endocrinology and Metabolism. 1964;24:1076–1082
  2. Drucker DJ. The biology of incretin hormones. Cell Metabolism. 2006;3:153–165
  3. Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–54
  4. Vilsboll T, Holst JJ. Incretins, insulin secretion and type-2 diabetes mellitus. Diabetologia. 2004;47:357–366
  5. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology. 2004;287:E199–E206
  6. Deacon CF. What do we know about the secretion and degradation of incretin hormones?. Regulatory Peptides. 2006;128:117–124
  7. Deacon CF. Circulation and degradation of GIP and GLP-1. Hormone and Metabolic Research. 2004;36:761–765
  8. Holz G. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic β-cells. Hormone and Metabolic Research. 2004;36:787–794
  9. Xu G, Stoffers DA, Habener JF, et al. Exendin 4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–2276
  10. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143:4397–4408
  11. Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Hormone and Metabolic Research. 2004;36:804–810
  12. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000;49:741–748
  13. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycemia. Diabetologia. 2003;46:798–801
  14. Nauck MA, Kleine N, Ørskov C, et al. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741–744
  15. Nakabayashi H, Nishizawa M, Nakagawa A, et al. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. American Journal of Physiology. 1996;271:E808–E813
  16. Balkan B, Liu X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. American Journal of Physiology. 2000;279:R1449–R1454
  17. Ahrén B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. American Journal of Physiology. 2004;286:R269–R272
  18. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–965
  19. Nyström T, Gutniak M, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type-2 diabetes patients with stable coronary artery disease. American Journal of Physiology. 2004;287:E1209–E1215
  20. Gutniak M, Ørskov C, Holst JJ, et al. Antidiabetic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. The New England Journal of Medicine. 1992;326:1316–1322
  21. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1[7-36 amide]) in patients with NIDDM. Diabetologia. 1996;39:1546–1553
  22. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type-2 diabetes: a parallel-group study. Lancet. 2002;359:824–830
  23. Ahrén B. Exenatide: a novel treatment of type-2 diabetes. Therapy. 2005;2:207–222
  24. Drucker DJ. Biologic actions and therapeutical potential of the proglucagon-derived peptides. Nature Clinical Practice. 2005;1:22–31
  25. Holst JJ. Glucagon-like ptpide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia. 2006;49:253–260
  26. Ahrén B. Inhibition of dipeptidyl peptidase-4 (DPP-4) – a novel approach to treat type-2 diabetes. Current Enzyme Inhibition. 2005;1:65–73
  27. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type-2 diabetes. Lancet. 2006;368:1696–1705
  28. Barnett A. DPP-4 inhibitors and their potential role in the management of type-2 diabetes. International Journal of Clinical Practice. 2006;60:1454–1470
  29. Meier JJ, Nauck MA. GIP as a potential therapeutic agent?. Hormone and Metabolic Research. 2004;36:859–866
  30. Mentlein R. Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regulatory Peptides. 1999;85:9–24
  31. Lambeir AM, Durinx C, Sharpe S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Critical Reviews In Clinical Laboratory Sciences. 2003;40:209–294
  32. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:6874–6879
  33. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type-2 diabetes. Diabetes. 1998;47:1663–1670
  34. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs. Diabetes. 1998;47:764–769
  35. Ahrén B, Holst JJ, Mårtensson H, et al. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. European Journal of Endocrinology. 2000;404:239–245
  36. Ahrén B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type-2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2078–2084
  37. Villhauer EB, Brinkman JA, Naderi GB, et al. 1[[(3-hydroxy-1-adamantyl)amino-]acetyl]-2-cyano-(s)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. Journal of Medicinal Chemistry. 2003;46:2774–2789
  38. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazol[4,3,a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type-2 diabetes. Journal of Medicinal Chemistry. 2005;48:141–151
  39. He YL, Balch A, Campestrini J. Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type-2 diabetes. Clinical Pharmacology and Therapy. 2005;56:19
  40. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clinical Pharmacology and Therapy. 2005;78:675–688
  41. Bergman AJ, Coyte J, Yi B. Effect of renal insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor. Clinical Pharmacology and Therapy. 2006;38:[abstr 46]
  42. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type-2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2006;91:4612–4619
  43. Burkey BE, Li X, Bolognese KL, et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. The Journal of Pharmacology and Experimental Therapy. 2005;315:688–695
  44. Mika M, Stashko M, Lubben T, et al. Acute DPP IV inhibition minimizes glucose and insulin response to a glucose challenge in a diabetic mouse. Diabetes. 2003;52(Suppl 1):A350
  45. Sörhede Winzell M, Ahrén B. The high-fat fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type-2 diabetes. Diabetes. 2003;53(Suppl 3):S215–S219
  46. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type-2 diabetes. Diabetes. 2006;55:1695–1704
  47. Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type-2 diabetes. Diabetes Care. 2002;25:869–875
  48. Ristic S, Byiers S, Foley J, et al. Improved glucaemic control with dipeptidyl peptidase-4 inhibition in patients with type-2 diabetes: vildagliptin (LAF237) dose response. Diabetes, Obesity & Metabolism. 2005;7:692–698
  49. Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type-2 diabetes. Hormone and Metabolic Research. 2006;387:423–438
  50. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type-2 diabetes. Diabetes Research and Clinical Practice. 2007;76:132–138
  51. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type-2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007;30:217–223
  52. Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with type 2 diabetes. Diabetic Medicine, in press.
  53. Hanefeld M, Herman G, Mickel C, et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type-2 diabetes. Diabetologia. 2005;49(Suppl 1):A287
  54. Scott R, Wu L, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type-2 diabetes. International Journal of Clinical Practice. 2007;61:171–180
  55. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type-2 diabetes mellitus. Diabetologia. 2006;49:2564–2571
  56. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type-2 diabetes. Diabetes Care. 2006;29:2632–2637
  57. Ahrén B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type-2 diabetes. Diabetes Care. 2004;27:2874–2880
  58. Bosi E, Camisaca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type-2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890–895
  59. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type-2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638–2643
  60. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity & Metabolism. 2007;9:194–205
  61. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazeone improves glycaemic control in patients with type-2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes, Obesity & Metabolism. 2007;9:166–174
  62. Rosenstock J, Brazg RG, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type-2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics. 2006;28:1556–1568
  63. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148–1155
  64. Mentlein R. Cell surface peptidases. International Review of Cytology. 2004;235:165–213
  65. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type-2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54:2988–2994
  66. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type-2 diabetes. The Journal of Clinical Endocrinology and Metabolic. 2005;90:4888–4894
  67. Ahrén B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type-2 diabetes over 1 year. Diabetes Care. 2005;28:1936–1940
  68. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. The Journal of Clinical Endocrinology and Metabolism. 2007;92:1249–1255
  69. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. The Journal of Clinical Endocrinology and Metabolism. 2002;87:1239–1246
  70. Azuma K., Radikova Z., Mancino J.M., et-al. DPP-4 inhibition improves insulin resistance (IR) in type 2 DM. ADA Session 2006; Late Breaking Abstract 5-LB.
  71. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52:741–750
  72. Duttaroy A, Voelker F, Zhang X, et al. The DPP-4 inhibitor vildagliptin increases β-cell mass in rodents. Diabetologia. 2005;48(Suppl 1):A178
  73. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type-2 diabetes. Diabetologia. 2006;49:2049–2057
  74. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type-2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2003;88:3082–3089
  75. Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase 4 inhibition on gastrointestinal function, meal appearance and glucose metabolism in type-2 diabetes. Diabetes. 2007;56:1475–1480

PII: S1521-690X(07)00058-9

doi: 10.1016/j.beem.2007.07.005

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 517-533 , December 2007

Article Tools

* Image Usage & Resolution